TAVR

Transcatheter aortic valve replacement (TAVR) is a key structural heart procedure that has rapidly expanded in the decade since it was first FDA cleared. TAVR has come a paradigm shift in how many aortic stenosis patients are treated, now making up more than 50% of U.S. aortic valve replacements. It is less invasive than open heart surgery and recovery times are greatly reduced. TAVR can also be used in patients who otherwise are too high risk to undergo surgery. TAVR is referred to as transcatheter aortic valve implantation (TAVI) in many placed outside of the U.S. TAVR inspired the growing areas of transcatheter mitral repair or replacement and transcatheter tricuspid valve repair and replacement.

RSS icon

TAVR outcomes after 1 year much worse for patients with valvular AFib

The study focused on more than 1,400 TAVR patients treated from August 2007 to June 2018. 

Thumbnail

The unlikely relationship between TAVR and chronic kidney disease

“The findings of this study will influence shared decision-making between chronic kidney disease patients and the heart team,” one specialist observed. 

Thumbnail

Endocarditis after TAVR: Increasingly rare, but incredibly fatal

The authors examined data from more than 134,000 TAVR patients, noting that 65% of endocarditis infections occurred within one year after the procedure. 

Thumbnail

TAVR outcomes similar after conscious sedation and general anesthesia

The new research out of Germany suggests both strategies are safe and effective for patients. 

Thumbnail

How population density can influence TAVR utilization, patient outcomes

Patient access to TAVR centers is often limited in rural areas where resources are in short supply.

Thumbnail

How patient-specific simulations can improve TAVR care

Overall, the simulations inspired clinicians to change part of the treatment plan for 16 of 42 patients.  

Thumbnail

Outcomes ‘worse than expected’ when TAVR fails and surgery is required

The mortality rate was 17% for patients undergoing SAVR following a failed TAVR. 

Thumbnail

Outcomes continue to be favorable for low-risk TAVR patients receiving self-expanding valve

Low-risk transcatheter atortic valve replacement (TAVR) patients with aortic stenosis who receive the Evolut PRO continue to experience outcomes comparable to surgery.

Displaying 385 - 392 of 416

Around the web

Health Imaging
Use of AI opportunistic screening in CT for cardiovascular disease

Ron Blankstein, MD, professor of radiology, Harvard Medical School, explains the use of artificial intelligence to detect heart disease in non-cardiac CT exams.

Health Imaging
New imaging protocols proposed to curb rise of cardiovascular infections

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.

Design by Adaptive Theme
Trimed Popup
Trimed Popup